Publication in the American Journal of Infection Control of a paper supporting the unprecedented microbial kill-rates of AsepticSure™ – an ozone vapor-based fumigant achieving ≥6 log₁₀ reductions for C. difficile, MRSA, VRE, E. coli and all other deadly bacterial pathogens tested – signals a promising new phase in the war against hospital and healthcare associated infections.
SAN FRANCISCO, CALIFORNIA – May 10, 2011 – Medizone International, Inc. (OTCBB:MZEI) (OTCQB:MZEI) announced today that the highly efficacious properties of its newly-developed disinfection and decontamination technology, AsepticSure™, have received mainstream validation by way of publication in the prestigious American Journal of Infection Control
The research paper – co-authored by Drs Dick Zoutman, MD, FRCPC; Michael Shannon, MA, MD, MSc; and Arkady Mandel MD, PhD, DSc – reveals how Medizone’s AsepticSure™ system, using a proprietary ozone-based process, creates a highly reactive oxidative vapor with high-level antimicrobial properties across a broad array of infectious disease-causing pathogens.
The methodology outlined in the peer review article involves the blending of Medizone’s patent pending combination of low dosage ozone gas with hydrogen peroxide vapor at specific relative humidity.
Full decontamination i.e. 100% microbial kill-rates measured as minimal reduction rates ranging from 6 – 7.9 log₁₀ was achieved in all bacteria and spores tested on steel discs in a test chamber as well as on cotton fabric. The same degree of efficacy was repeated in Medizone’s 81 cubic meter full scale test room and then duplicated in a 90 cubic meter hospital room.
Dr Shannon, President and Director of Medical Affairs for Medizone commented, “This synergistic effect was noted for all 4 vegetative bacteria we tested – MRSA, VRE, E. coli and P. aeruginosa – to the point where 100% decontamination levels were consistently achieved within 30 minutes of exposure.
Bacterial kill-rates of this magnitude are unprecedented in relation to the relatively low concentration of ozone and short durations used. So too are the 100% kill-rates achieved with the spores of C. difficile and B. subtilis (the study surrogate for Anthrax) NB: 6 – 7 log₁₀ reductions were attained under identical test conditions with only slightly longer exposure periods of 45 – 90 minutes respectively.
CEO Edwin Marshall, added, “The publication of these findings in a prestigious peer review journal is a pivotal moment for the future of AsepticSure™. It is also a historic moment in the 125 year long search for an ozone-based disinfectant that not only meets all mainstream standards of efficacy and safety, but outperforms them!
Going forward, the validation of the science behind AsepticSure™ paves the way for Dr Zoutman’s presentation to the World Health Organization-sponsored ‘First International Conference on Prevention and Infection Control’ in Geneva at the end of June. It also underpins the many other national and international medical conference presentations planned for this year and beyond.”
Marshall concluded, “Given how close we now are to the launch of AsepticSure’s global commercialization phase, the publication of such a ground-breaking study in a peer review journal of this caliber is hugely exciting for the company, its shareholders and the market sectors that stand to benefit from it.”
For press information on Medizone International, please contact:
Bruce Smeaton, Investor Relations, Medizone International, Inc.
T: 001-415-331-0202 E: email@example.com
Medizone International, Inc. is engaged in final production development of its modular design AsepticSure™ Decontamination Systems. Decontamination to the sterilization standard of >6 log is obtainable within hospitals, long term care facilities, food processing plants, clean room manufacturing facilities, schools and other critical infrastructure. A government variant is being developed for bio-terrorism counter measures including building remediation.
This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.